[1] |
World Health Organization. Global tuberculosis report 2019. Geneva: World Health Organization, 2019.
|
[2] |
赵皎洁, 陆宇 . 抗结核药物药代动力学/药效学的研究及进展. 中国防痨杂志, 2019,41(6):700-704.
|
[3] |
郑梅琴, 陆宇, 王彬 , 等. Alamar blue法检测药物细胞内抗结核活性的研究. 中国抗生素杂志, 2011,36(6):468-473.
|
[4] |
Peloquin CA, Jaresko GS, Yong CL , et al. Population pharmacokinetic modeling of isoniazid, rifampin, and pyrazinamide. Antimicrob Agents Chemother, 1997,41(12):2670-2679.
|
[5] |
Zhang Y, Huo M, Zhou J , et al. PKSolver: An add-in program for pharmacokinetic and pharmacodynamic data analysis in Microsoft Excel. Comput Methods Programs Biomed, 2010,99(3):306-314.
|
[6] |
Meibohm B, Derendorf H . Pharmacokinetic/pharmacodynamic studies in drug product development. J Pharm Sci, 2002,91(1):18-31.
|
[7] |
Srivastava S, Gumbo T . In vitro and in vivo modeling of tuberculosis drugs and its impact on optimization of doses and regimens. Curr Pharm Des, 2011,17(27):2881-2888.
|
[8] |
Schuck EL, Derendorf H . Pharmacokinetic/pharmacodynamic evaluation of anti-infective agents. Expert Rev Anti Infect Ther, 2005,3(3):361-373.
|
[9] |
Lister PD . The role of pharmacodynamic research in the assessment and development of new antibacterial drugs. Biochem Pharmacol, 2006,71(7):1057-1065.
|
[10] |
Gumbo T, Pasipanodya JG, Nuermberger E, et al. Correlations Between the Hollow Fiber Model of Tuberculosis and Therapeutic Events in Tuberculosis Patients: Learn and Confirm. Clin Infect Dis, 2015,61 Suppl 1: S18-24.
|
[11] |
Cavaleri M, Manolis E. Hollow Fiber System Model for Tuberculosis: The European Medicines Agency Experience. Clin Infect Dis, 2015,61 Suppl 1: S1-4.
|
[12] |
郎美琦, 蒋利, 黄佳盛 . 抗结核病药物治疗综述. 临床肺科杂志, 2010,15(8):1153-1154.
|
[13] |
Jindani A, Doré CJ, Mitchison DA . Bactericidal and Sterilizing Activities of Antituberculosis Drugs during the First 14 Days. Am J Respir Crit Care Med, 2003,167(10):1348-1354.
|
[14] |
Jindani A, Aber VR, Edwards EA , et al. The Early Bactericidal Activity of Drugs in Patients with Pulmonary Tuberculosis. Am Rev Respir Dis, 1980,121(6):939-949.
|
[15] |
Viveiros M, Portugal I, Bettencourt R , et al. Isoniazid-Induced Transient High-Level Resistance in Mycobacterium tuberculosis. Antimicrob Agents Chemother, 2002,46(9):2804-2810.
|
[16] |
Wallis RS, Patil S, Cheon SH , et al. Drug tolerance in Mycobacterium tuberculosis. Antimicrob Agents Chemother, 1999,43(11):2600-2606.
|
[17] |
Srivastava S, Musuka S, Sherman C , et al. Efflux-pump-derived multiple drug resistance to ethambutol monotherapy in Mycobacterium tuberculosis and the pharmacokinetics and pharmacodynamics of ethambutol. J Infect Dis, 2010,201(8):1225-1231.
|
[18] |
Boshoff HI1, Reed MB, Barry CE 3rd , et al. DnaE2 Polymerase Contributes to In Vivo Survival and the Emergence of Drug Resistance in Mycobacterium tuberculosis. Cell, 2003,113(2):183-193.
|
[19] |
Warner DF, Mizrahi V . Tuberculosis Chemotherapy: the Influence of Bacillary Stress and Damage Response Pathways on Drug Efficacy. Clin Microbiol Rev, 2006,19(3):558-570.
|
[20] |
Deshpande D, Pasipanodya JG, Mpagama SG , et al. Ethionamide Pharmacokinetics/Pharmacodynamics-derived Dose, the Role of MICs in Clinical Outcome,the Resistance Arrow of Time in Multidrug-resistant Tuberculosis. Clin Infect Dis, 2018,67 Suppl 3: S317-326.
|
[21] |
Donald PR, Sirgel FA, Botha FJ , et al. The Early Bactericidal Activity of Isoniazid Related to Its Dose Size in Pulmonary Tuberculosis. Am J Respir Crit Care Med, 1997,156(3 Pt 1):895-900.
|
[22] |
Jayaram R, Shandil RK, Gaonkar S , et al. Isoniazid Pharmacokinetics-Pharmacodynamics in an Aerosol Infection Model of Tuberculosis. Antimicrob Agents Chemother, 2004,48(8):2951-2957.
|
[23] |
Donald PR, Sirgel FA, Venter A , et al. The Influence of Human N-Acetyltransferase Genotype on the Early Bactericidal Activity of Isoniazid. Clin Infect Dis, 2004,39(10):1425-1430.
|
[24] |
Gumbo T, Louie A, Liu W , et al. Isoniazid Bactericidal Activity and Resistance Emergence: Integrating Pharmacodynamics and Pharmacogenomics to Predict Efficacy in Different Ethnic Populations. Antimicrob Agents Chemother, 2007,51(7):2329-2336.
|